fbpx Yourgene Health plc - Home
Infectious Disease
Clarigene® RUO
Clarigene® CE-IVD
Clarigene® SARS-CoV-2 CE-IVD
Clarigene® Feature Notes
Clinical Performance
Clinical Performance Data
Benefits of the IONA® Nx NIPT Workflow
IONA® Software
Atlas Workflow Manager
Technical Support
Quality and Regulatory
Choose IONA® Nx NIPT Workflow
the IONA® test
Clinical Performance
Application Support
Choose IONA®
Contact Us
Laboratory Customer Login
Sage™ Prenatal Screen
For Clinical Laboratories
Clinical Performance
Choose Sage™
Sage QS 32plex
For Pregnant Women
Advantages of the Sage™ prenatal screen
Who can have the Sage™ test
For Healthcare Professionals
Who can have the Sage™ test
Clinical Performance
Clinical Performance
Contact Us
Reproductive Health
Cystic Fibrosis
Cystic Fibrosis Analysis
Choose CF-EU2
Male Infertility
Pregnancy Loss
Rapid Aneuploidy Analysis
QST*R Range
QST*R Feature Notes
Thrombosis Risk Panel
Precision Medicine
Elucigene DPYD
DPYD Overview
DPYD Testing Workflow
Clinical Performance
Choose Elucigene DPYD
Yourgene Flex™
DNA Size Selection / Enrichment
Ranger® Technology
Why Choose Ranger®
Get to the DNA you care about in NIPT
Get to the DNA you care about in Liquid Biopsy
LightBench® Feature Notes
Yourgene® QS250
Yourgene® SP150

Features Vs Benefits

FeaturesBenefit to customer/end user
CE-IVD kit* Reliable
6 clinically relevant variants in line with current CPIC Guidelines (including full HapB3 phasing)​ Clinical utility
4 hour workflow Fast TAT – results within 1 day in line with oncology care pathways
Two tube analysis Simple set up, minimal hands on time
Kit includes just 4 tubes needed for workflow Simple to set up
Internal control and STR markers for each tube included Reliable results
Compatible with ABI 3*** Genetic Analysers and SeqStudio Ease of use and workflow integration
Data review using GeneMarker®  and GeneMapper™ software (no data transfer required) Ease of interpretation
YGH technical team Tech support available
YGH manufactured Reliable supply chain

Clinical UtilityClinical Utility Diagram and explanation

Economic Utility Economic Utility Diagram and explanation

Key Strategic Partnerships

  • All Wales Medical Genomics Service (AWMGS) commenced a pilot phase earlier this year testing all patients prior to 5-FU treatment. The pilot was successful, leading to the launch of the service in October 2020. It has led to all health boards across Wales routinely offering the DPYD test to cancer patients, of which Yourgene is the sole provider. View press release here
    • Wales is the first nation in the UK to implement this screening programme and offer the DPYD test to all patients, with over 400 samples already taken and 6% of patients coming back positive 
    • Yourgene will be providing the Elucigene DPYD tests to screen for approximately 200 patients each month for the next year. If 2,400 patients are screened, at the positive rate of 6% continues, we anticipate 144 cancer patients will be prevented from having toxic chemotherapy reactions 
  • NHS England published a Clinical Commissioning Urgent Policy Statement in November 2020 recommending the routine availability of DPYD testing prior to the start of treatment with the chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects. 
  • In January 2021 a research article was published titled ‘Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).’ This article endorses screening for DPD deficiency. View press release here 
    • Yourgene already supplies its Elucigene DPYD test directly into Belgium, including to the University Hospital St Luc/ UCLouvain, Woluwe, Belgium, where the lead author of the research publication is based. 
  • In Feburary 2021 it was announced that all cancer patients in Northern Ireland will be routinely screened for DPD deficiency ahead of starting certain chemotherapy treatments. Read more here.
  • View our “Your Comment” blog post on The role of DPYD testing in managing a successful response to the COVID-19 pandemic
 *Also available as RUO (Research Use Only), This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.

DYPD screening has been recommended in Belgium, Germany, Wales and by NHS England.